M. Maitituoheti

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

The Androgen Receptor: A Therapeutic Target in Desmoplastic Small Round Cell Sarcoma

The paper shows that DSRCT is driven by the androgen receptor and responds to androgen deprivation therapy.

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

Chromatin State Dynamics Confers Specific Therapeutic Strategies in Enhancer Subtypes of Colorectal Cancer

This study identifies enhancer subtypes in colorectal cancer through epigenomic analysis and proposes targeted therapeutic strategies based on these subtypes.

Bivalent and Broad Chromatin Domains Regulate Pro-metastatic Drivers in Melanoma

The paper identifies bivalent chromatin states and broad H3K4me3 domains associated with pro-metastatic drivers in melanoma using ChIP-sequencing data from tumor samples and cell lines.

Super-enhancer impairment is a link between MLL4 inactivated lung tumors and their vulnerability to glycolysis pathway inhibition

The paper shows that MLL4 loss in lung cancer promotes glycolysis and that inhibiting glycolysis selectively targets MLL4-mutant lung tumors.

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma

This study identifies KMT2D as a tumor suppressor in melanoma, showing its loss leads to metabolic reprogramming toward glycolysis and dependence on IGF signaling, suggesting therapeutic targeting of these pathways.